Quest Diagnostics Unveils Groundbreaking ctDNA MRD Test for Enhanced Cancer Monitoring
- Quest Diagnostics will present research on ctDNA MRD testing at the 2026 ASCO Gastrointestinal Cancers Symposium in January.
- The Haystack MRD® test aims to improve cancer monitoring for patients with colorectal cancer and rectal adenocarcinoma.
- Quest Diagnostics emphasizes the significance of ctDNA MRD testing for earlier cancer recurrence detection and personalized treatment strategies.
Quest Diagnostics Advances Cancer Monitoring with ctDNA Technology
Quest Diagnostics, a leading provider of diagnostic information services, prepares to present groundbreaking research on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 8-10. Central to the presentation is the Haystack MRD® test, developed by Haystack Oncology, a subsidiary of Quest Diagnostics. This innovative test represents a significant advancement in cancer monitoring, particularly for patients with colorectal cancer and rectal adenocarcinoma. The symposium will highlight two pivotal studies that explore the efficacy of tumor-informed MRD assays, showcasing their potential to revolutionize early detection of cancer recurrence.
The first study focuses on the reproducibility and clinical concordance of the Haystack MRD test in patients who have undergone surgical resection for colorectal cancer. This aspect is crucial, as accurate and reliable MRD testing can inform clinicians about the presence of residual cancer, aiding in timely interventions. The second study delves into the role of ctDNA in monitoring patients receiving total neoadjuvant treatment for locally advanced rectal adenocarcinoma, emphasizing the importance of ctDNA in real-time treatment assessment. The ability to track cancer progression through non-invasive blood tests highlights a paradigm shift in cancer management, allowing for personalized treatment strategies based on real-time data.
A recent survey conducted by Harris Poll reveals that 96% of oncologists believe that MRD testing can detect cancer recurrence earlier than traditional methods. This statistic underscores the growing consensus in the medical community regarding the importance of ctDNA MRD testing in enhancing patient outcomes. By analyzing trace amounts of tumor-derived DNA found in the bloodstream, clinicians can identify residual or recurring cancer, enabling them to adjust surveillance and treatment plans proactively. Early intervention can significantly improve patient prognosis, making ctDNA MRD testing an invaluable tool in the fight against cancer.
In addition to its clinical implications, the Haystack MRD test boasts exceptional sensitivity and specificity, having been developed over two decades in collaboration with experts from Johns Hopkins School of Medicine. The test is validated for commercial use in a CLIA-certified laboratory and is accessible for clinical trials in various international locations, including Baltimore, Hamburg, and Helsinki. As the medical field increasingly embraces ctDNA-based MRD testing, Quest Diagnostics stands at the forefront of this transformative movement, promising to enhance cancer management and improve patient care through innovative diagnostic solutions.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

